investor center media global distributors contact us ordering purchase products Products & Services Science Development Company Products & Services News & Features Join Our Community All Products & Services Research Use Only (RUO) CE-Marked Assays View all products Relevant Publications 2014 Product Catalog! Request our 2014 product catalog Wall Charts Request a complimentary copy: Hematologic Malignancy Testing Algorithm Clonality Testing Strategy Notice: Acute Myeloid Leukemia (AML) The FDA has made it clear that a FLT3 companion diagnostic is required for approval of any FLT3-targeted or FLT3-stratified therapy. LabPMM is the only clinical laboratory with access to the patents required to develop and offer a FLT3 companion diagnostic for worldwide use. Personalized Medicine & IVS Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, LabPMM, we provide worldwide access to molecular biomarker testing, which enables pharmaceutical companies to bring to the market new targeted treatments, and allows physicians to better determine optimal treatment for their patients. Research & Biotechnology Development & Partnering Companion Diagnostics New NGS LymphoTrack® Assays! The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded to include assays for the detection of IGH Somatic Hypermutation on the Ion PGM™ as well as a suite of assays which allow testing of TRG and IGH simultaneously in a single run on the MiSeq® or the Ion PGM. These assays were all designed for easy integration into a laboratory workflow and include bioinformatics software that allows for easy and streamlined data analysis. Using these assays, both the DNA sequences and frequency distributions of B- and T-cell rearrangements can be obtained. Contact us for more information. LymphoTrack® Assays for the Ion PGM™ - Now available! The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded beyond our current MiSeq formatted product line to include assays for TRG and IGH on the Ion PGM™. These assays were designed for easy integration into the laboratory workflow, and include a bioinformatics software that allows for simple and streamlined data analysis providing both DNA sequences and frequency distributions of B- and T-cell rearrangements. Contact us for more information. View a video of our AMP 2013 Workshop! We have posted a condensed version of our AMP workshop entitled Clonality Testing by Next-Generation Sequencing: Latest Developments from the New Frontier. This talk was given to a capacity audience in Phoenix, AZ in November 2013, and now you can enjoy highlights at your own convenience. Click here to view. LymphoTrack® IGH Assay Launched Invivoscribe has expanded its portfolio of next-generation sequencing (NGS) products with the introduction of the LymphoTrack® IGH Assay (for MiSeq platform). This assay provides unprecedented levels of information in the form of frequency distributions and DNA sequences of rearranged IGH genes. Click here for more information. Contact us to learn more. In the News We are excited to announce that LabPMM®, our subsidiary reference laboratories in the US and the EU, now offer the only standardized, internationally harmonized and licensed FLT3 Signal Ratio Assay. Our FLT3 signal ratio (SR) assay tests for both ITD and TKD mutations, providing signal ratios for ITD mutations by comparing the signal intensity of the mutant and wild type amplicon products. CAP Today The Feature Story in the May 2013 issue of CAP Today titled: “Molecular clonality testing for lymphoma” highlights the benefits of PCR-based B and T cell clonality assays from Invivoscribe. Click here to view the article. LabPMM and New York LabPMM is happy to announce that we have received our New York state clinical lab license. Please contact us with any questions. Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Menu. Click here to learn more about Genection. January 8, 2014 Invivoscribe embraces the value of constant process improvement July 16, 2013 Marketwired Invivoscribe FLT3 Method Patent Claims Upheld June 19, 2013 Marketwired Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling View all News Invivoscribe Companies Meetings and Conferences November 12, 2014 Corporate Workshop AMP 2014 Annual Meeting National Harbor, MD, USA November 13-15, 2014 AMP 2014 Annual Meeting National Harbor, MD, USA December 6-9, 2014 2014 ASH Annual Meeting and Exposition Moscone Center, San Francisco, CA, USA View all Events privacy policy terms & conditions code of conduct © 2014 Invivoscribe